In a report issued today, the Government Accountability Office recommended that the Health Resources and Services Administration take additional steps to ensure contract pharmacies comply with 340B drug savings program requirements. Requested by Republican leaders of the House Energy and Commerce Committee, the report reviews the use of contract pharmacies in the 340B program. HRSA concurs in the report with GAO recommendations that it issue guidance on preventing duplicate discounts under Medicaid managed care and assess compliance, and issue more specific guidance regarding contract pharmacy oversight. The agency also agreed with a GAO recommendation to issue guidance on the length of time covered entities must look back following an audit to identify the full scope of noncompliance identified during the audit. HRSA disagreed in the report with a GAO recommendation that it require covered entities to register contract pharmacies for each site of the entity for which a contract exists, and with recommendations that audited covered entities provide certain additional information.

Headline
A bipartisan group of senators Aug. 5 introduced the Supporting Underserved and Strengthening Transparency, Accountability and Integrity Now and for the Future…
Headline
The Department of Health and Human Services today issued a notice announcing a revised 340B Rebate Model Pilot Program, allowing qualifying drug manufacturers…
Headline
The U.S. District Court for the District of Columbia July 21 upheld a lower court’s decision that Section 340B of the Public Health Service Act does not …
Headline
The AHA July 14 urged the Health Resources and Services Administration to revise its estimate of the administrative burden associated with the agency’s…
Headline
The AHA today filed a friend-of-the-court brief supporting the Department of Health and Human Services’ motion to dismiss AbbVie’s lawsuit …
Headline
The Health Resources and Services Administration announced that 340B covered entities purchased $100 billion in outpatient drugs under the federal 340B Drug…